Is your decision to prescribe empagliflozin for CKD patients without albuminuria influenced by a recent cost-utility analysis showing that empagliflozin was not cost-effective for this group?  

I have not been a proponent of using SGLT2 for patients who do not have proteinuria to begin with. I don't think these patients would benefit much, just as the data for ACE/ARB in these groups of patients is not great. Usually, they progress fairly slowly anyway.

I have not been in the habit of prescribing these medications in the absence of proteinuria.